ABSTRACT
We have investigated the mechanism of inhibition of the new group I mGluR antagonists CPCCOEt and MPEP and determined that both compounds have a non-competitive mode of inhibition. Furthermore using chimeric/mutated receptors constructs we have found that these antagonists act at a novel pharmacological site located in the trans-membrane (TM). Specific non-conserved amino acid residues in the TM domain have been identified which are necessary for the inhibition by CPCCOEt and MPEP of the mGlul and mGlu5 receptors, respectively. Using molecular modeling a model of the TM domain was built for both mGlu1 and mGlu5 receptor subtypes. Docking of CPCCOEt and MPEP into their respective model allowed the modelisation of the novel binding site.
Subject(s)
Receptors, Metabotropic Glutamate/antagonists & inhibitors , Binding Sites , Models, Molecular , Receptors, Metabotropic Glutamate/chemistrySubject(s)
B-Lymphocytes/immunology , Cyclosporine/pharmacology , Graft Rejection/immunology , Immunosuppressive Agents/pharmacology , Lymphocyte Activation/drug effects , Pyrazoles/pharmacology , Transplantation, Heterologous/immunology , Aniline Compounds/pharmacology , Animals , Antigens, Heterophile/immunology , B-Lymphocytes/drug effects , Biphenyl Compounds/pharmacology , Cell Division/drug effects , Crotonates , Drug Resistance , Hydroxybutyrates/pharmacology , Isoxazoles/pharmacology , Leflunomide , Lymphocyte Activation/immunology , Lymphoma, B-Cell , Mycophenolic Acid/pharmacology , Nitriles , Primates , Swine , T-Lymphocytes/immunology , Toluidines , Tumor Cells, CulturedABSTRACT
Racemic CPCCOEt ((1aRS,7aRS)-2-hydroxyimino-1a, 2-dihydro-1H-7-oxacyclopropa[b]naphthalene-7a-carboxylic acid ethyl ester, (+/-)-1) derivatives have been shown to be subtype-selective metabotropic glutamate (mGlu) 1 receptor antagonists (Annoura et al. Bioorg. Med. Chem. Lett. 1996, 6, 763-766). The optical isomers of (+/-)-1 have been separated by chromatography on a chiral stationary phase. The absolute configuration at the C-1a and C-7a positions was determined using X-ray crystallography of an amide derivative with the methyl ester of L-phenylalanine (L-PheOMe) ((+)-6). In a phosphoinositol (PI) turnover assay at the cloned human mGlu1b receptor, (-)-1 and the new amide derivatives (-)-5 and (-)-6, all of which have (1aS,7aS)-stereochemistry on the chromane ring system, showed IC(50) values of 1.5, 0.43, and 0.93 microM, respectively. In contrast, (+)-1 and the new amide derivatives (+)-5 and (+)-6were found to be inactive up to a concentration of 30 microM indicating a selectivity for the (-)-enantiomers of at least 70-fold. In a previous study (Litschig et al. Mol. Pharmacol. 1999, 55, 453-461) we demonstrated using site-directed mutagenesis that the interaction site of (+/-)-1 is located in the transmembrane (TM) domain of hmGlu1b. To suggest a plausible binding mode of (-)-1, we have built a molecular mechanics model of the putative seven TM domain of hmGlu1 based on the alpha-carbon template of the TM helices of rhodopsin. A receptor docking hypothesis suggests that the OH of T815 (TMVII) comes in close contact with the oxime OH of (-)-1 and (-)-5, whereas no such close interactions could be demonstrated by docking of (+)-1.
Subject(s)
Chromones/chemical synthesis , Excitatory Amino Acid Antagonists/chemical synthesis , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Amino Acid Sequence , Animals , Binding Sites , CHO Cells , Chromones/chemistry , Chromones/pharmacology , Cricetinae , Crystallography, X-Ray , Excitatory Amino Acid Antagonists/chemistry , Excitatory Amino Acid Antagonists/pharmacology , Hydrolysis , Inositol Phosphates/metabolism , Models, Molecular , Molecular Sequence Data , Mutagenesis, Site-Directed , Receptors, Metabotropic Glutamate/chemistry , Stereoisomerism , Structure-Activity RelationshipABSTRACT
We have investigated the mechanism of inhibition and site of action of the novel human metabotropic glutamate receptor 5 (hmGluR5) antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP), which is structurally unrelated to classical metabotropic glutamate receptor (mGluR) ligands. Schild analysis indicated that MPEP acts in a non-competitive manner. MPEP also inhibited to a large extent constitutive receptor activity in cells transiently overexpressing rat mGluR5, suggesting that MPEP acts as an inverse agonist. To investigate the molecular determinants that govern selective ligand binding, a mutagenesis study was performed using chimeras and single amino acid substitutions of hmGluR1 and hmGluR5. The mutants were tested for binding of the novel mGluR5 radioligand [(3)H]2-methyl-6-(3-methoxyphenyl)ethynyl pyridine (M-MPEP), a close analog of MPEP. Replacement of Ala-810 in transmembrane (TM) VII or Pro-655 and Ser-658 in TMIII with the homologous residues of hmGluR1 abolished radioligand binding. In contrast, the reciprocal hmGluR1 mutant bearing these three residues of hmGluR5 showed high affinity for [(3)H]M-MPEP. Radioligand binding to these mutants was also inhibited by 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester (CPCCOEt), a structurally unrelated non-competitive mGluR1 antagonist previously shown to interact with residues Thr-815 and Ala-818 in TMVII of hmGluR1. These results indicate that MPEP and CPCCOEt bind to overlapping binding pockets in the TM region of group I mGluRs but interact with different non-conserved residues.
Subject(s)
Chromones/metabolism , Excitatory Amino Acid Antagonists/metabolism , Pyridines/metabolism , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Amino Acid Sequence , Animals , Binding Sites , CHO Cells , COS Cells , Cricetinae , Models, Molecular , Molecular Sequence Data , Rats , Receptors, Metabotropic Glutamate/chemistry , Receptors, Metabotropic Glutamate/metabolism , Structure-Activity RelationshipABSTRACT
Application of a modified ePHOGSY and other NMR experiments to an H2O-DMSO solution of the protein FKBP12 identified the presence of one molecule of DMSO bound in the substrate binding site. It occupies the same spatial region occupied by the pipecolidine moiety of the immunosuppressive drugs FK506 and Rapamycin complexed to the protein. The binding constant K(D) for ths DMSO molecule was only 275 mM. A substructure search of small molecules similar to DMSO resulted in the identification of molecules with improved binding affinity. This work represents a clear example of the powerful interplay of molecular modelling and NMR.
Subject(s)
Dimethyl Sulfoxide/pharmacokinetics , Immunophilins/chemistry , Protein Conformation , Binding Sites , Dimethyl Sulfoxide/chemistry , Immunophilins/metabolism , Kinetics , Models, Molecular , Nuclear Magnetic Resonance, Biomolecular/methods , Solutions , Solvents , Tacrolimus/pharmacokinetics , Tacrolimus Binding ProteinsABSTRACT
T-cell immunosuppressant-based therapies efficiently control early graft rejection in allotransplantation settings. They fail, however, to prevent those rejection events which are mediated by transplant-induced antibody (Ab) responses such as those involved in xenograft and chronic allograft rejection. This is mainly due to their inability to block T-cell-independent Ab production against the transplanted organs. The bioactive metabolite 2(Z) of leflunomide (1) inhibits the formation of such Ab, but the drug has pharmacokinetic properties and a therapeutic window incompatible with transplantation indications. Pyrazole 3, a constrained analogue of 2(Z), was designed and shown to be conformationally and biologically similar to 2(Z). Further investigations with derivatives of 3 demonstrated that the pyrazoles had very tight structure-activity relationships, the only equipotent compound being 3o. However, in contrast to 2(Z), both 3 and 3o were inactive in vivo due to short half-life and drug concentrations lower than the in vitro obtained IC50 values. Compound 3o inhibits T-cell-independent Ab production by a different biochemical mechanism from that of 2(Z) and 3 and may therefore represent a valuable tool for the identification of new targets for B-cell inhibition.
Subject(s)
B-Lymphocytes/drug effects , Graft Rejection/prevention & control , Immunosuppressive Agents , Isoxazoles/chemistry , Oxidoreductases Acting on CH-CH Group Donors , Pyrazoles , Transplantation, Heterologous/immunology , Administration, Oral , Animals , Antigens, T-Independent/immunology , B-Lymphocytes/immunology , Cell Division/drug effects , Cell Division/immunology , Dihydroorotate Dehydrogenase , Graft Rejection/immunology , Humans , Immunoglobulin G/immunology , Immunoglobulin M/immunology , Immunosuppressive Agents/chemical synthesis , Immunosuppressive Agents/chemistry , Immunosuppressive Agents/pharmacokinetics , Immunosuppressive Agents/pharmacology , In Vitro Techniques , Injections, Intravenous , Isoxazoles/pharmacology , Jurkat Cells/cytology , Jurkat Cells/immunology , Leflunomide , Lipopolysaccharides/immunology , Lymphocyte Culture Test, Mixed , Mice , Oxidoreductases/antagonists & inhibitors , Pyrazoles/administration & dosage , Pyrazoles/chemical synthesis , Pyrazoles/pharmacokinetics , Pyrazoles/pharmacology , Structure-Activity RelationshipABSTRACT
The indolonaphthyridine 8 is described as a selective 5-HT2C/2B vs 5-HT2A receptor antagonist. The compound was synthesized in seven steps starting from indoline and isonicotinic acid chloride. The key step is a photocyclization of the indolinyl tetrahydropyridinocarbamic acid ethyl ester 4 to the cis-octahydroindolo[1, 7-bc][2,6]naphthyridinecarbamic acid ethyl ester 5. The synthesis was accomplished by reduction with aluminum hydride and racemic resolution. The indolonaphthyridine 8 exerted the binding profile of a selective 5-HT2C receptor ligand (pKD 7.8) and behaved as an antagonist on the 5-HT-induced accumulation of inositol phosphates in pig choroid plexus cells (pKB 7.13). Compound 8 dose-dependently inhibited the ACTH response to MK-212 in rats and the MK-212-induced hypophagic effect with an ID50 value of 0.3 mg/kg sc. Compound 8 acted as a 5-HT2B receptor antagonist at the rat stomach fundus with a pKB value of 7.34.
Subject(s)
Naphthyridines/chemical synthesis , Naphthyridines/pharmacology , Serotonin Antagonists/chemical synthesis , Serotonin Antagonists/pharmacology , Animals , Kinetics , Male , Rats , Rats, Inbred WKY , Rats, Sprague-Dawley , Serotonin Antagonists/metabolismABSTRACT
4,6,6a,7,8,12b-Hexahydroindolo[4,3-ab]phenanthridines ("benzergolines") was the first structural class of potent and selective dopamine D1 agonists lacking a catechol group. In order to determine the enantioselectivity of the 7-methyl derivative in the adenylate cyclase assay, its 5,5a-dihydro precursor was resolved and both enantiomers oxidized to the final products. The biological activity was found to reside entirely in the (-)-enantiomer, (-)-1 (CY 208-243). An X-ray study of its (-)-mandelic acid salt revealed a 6aR,12bR absolute configuration, which, in confirmation of the structure hypothesis, corresponds to that of the ergolines. Unexpectedly, an axial conformation of the N-methyl group was observed in the crystal structure. In contrast, subsequently analyzed crystals of the free base of (-)-1 revealed an equatorial conformation of the N-methyl group, which, we assume, represents the bioactive conformation. Based on the determined absolute configuration, (-)-1 could be oriented in a previously described "rotamer-based dopamine receptor model", which allowed the localization of a "subtype selectivity-inducing site" (aryl binding site at the D1 receptor, steric barrier at the D2 receptor), marked by the conformationally fixed "additional" phenyl group of the benzergoline molecule.
Subject(s)
Dopamine Agents/pharmacology , Indoles/pharmacology , Phenanthridines/pharmacology , Adenylyl Cyclases/metabolism , Animals , Brain/drug effects , Brain/metabolism , Cattle , Dopamine Agents/chemistry , Indoles/chemistry , Models, Molecular , Molecular Conformation , Phenanthridines/chemistry , Rats , Stereoisomerism , Structure-Activity RelationshipABSTRACT
Pilocarpine isosteres have been synthesized and characterized with regard to their in vitro muscarinic properties. The results indicate that the carbonyl oxygen of the lactone function of pilocarpine is of primary importance for agonist activity with the ether oxygen being of lesser or secondary importance. An X-ray structure determination for the hydrogen O,O'-ditoluoyltartrate salt of thiolactone pilocarpine isostere 2a has been performed. This compound has an unusual pharmacological profile exhibiting M1-agonist selectivity as well ass presynaptic antagonism. As a result this compound is also viewed as having therapeutic potential for Alzheimer's disease. A model for the binding of pilocarpine and other muscarinic agonists to the third transmembrane helix of the human m1 muscarinic receptor has been developed.
Subject(s)
Lactams/chemical synthesis , Parasympathomimetics/chemical synthesis , Pilocarpine/analogs & derivatives , Receptors, Muscarinic/metabolism , Sulfhydryl Compounds/chemical synthesis , Animals , Binding, Competitive , Crystallography , Guinea Pigs , Lactams/metabolism , Male , Mice , Models, Biological , Parasympathomimetics/metabolism , Rats , Rats, Inbred Strains , Stereoisomerism , Structure-Activity Relationship , Sulfhydryl Compounds/metabolismABSTRACT
Pre-treatment with zinc aspartate protected mice against the lethal effects of radiation and raised the LD50 from 8 Gy to 12.2 Gy. Zinc chloride and zinc sulphate were clearly less active. The radioprotective effect of zinc aspartate was equivalent to cysteamine and slightly inferior to S,2-aminoethylisothiourea (AET). Zinc aspartate displayed a similar therapeutic index to the thiols but could be applied at an earlier time before irradiation. Synergistic effects occurred with the combined administration of zinc aspartate and thiols. By giving zinc aspartate with cysteamine, the LD50 was increased to 13.25 Gy and, by combining it in the optimal protocol with AET, to 17.3 Gy. The radioprotection by zinc and its synergism with thiols is explained by the stabilisation of thiols through the formation of zinc complexes.